Namibia

Namibia

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
4.19 (4.13 - 4.24) 2019 Modelled IHME
4.51 (4.45 - 4.56) 2018 Modelled IHME
4.7 (4.64 - 4.77) 2017 Modelled IHME
4.77 (4.72 - 4.83) 2016 Modelled IHME
4.84 (4.78 - 4.90) 2015 Modelled IHME
4.96 (4.90 - 5.02) 2014 Modelled IHME
5.14 (5.08 - 5.20) 2013 Modelled IHME
5.34 (5.27 - 5.40) 2012 Modelled IHME
5.55 (5.47 - 5.62) 2011 Modelled IHME
5.73 (5.65 - 5.82) 2010 Modelled IHME
5.91 (5.83 - 6) 2009 Modelled IHME
6.09 (6.01 - 6.19) 2008 Modelled IHME
6.27 (6.17 - 6.37) 2007 Modelled IHME
6.42 (6.31 - 6.53) 2006 Modelled IHME
6.53 (6.40 - 6.65) 2005 Modelled IHME
6.6 (6.48 - 6.72) 2004 Modelled IHME
6.65 (6.54 - 6.77) 2003 Modelled IHME
6.7 (6.58 - 6.82) 2002 Modelled IHME
6.74 (6.63 - 6.88) 2001 Modelled IHME
6.8 (6.68 - 6.94) 2000 Modelled IHME
6.87 (6.75 - 7.01) 1999 Modelled IHME
6.96 (6.84 - 7.09) 1998 Modelled IHME
7.04 (6.92 - 7.17) 1997 Modelled IHME
7.13 (7 - 7.25) 1996 Modelled IHME
7.21 (7.07 - 7.34) 1995 Modelled IHME
7.29 (7.16 - 7.42) 1994 Modelled IHME
7.37 (7.24 - 7.50) 1993 Modelled IHME
7.45 (7.32 - 7.58) 1992 Modelled IHME
7.53 (7.39 - 7.68) 1991 Modelled IHME
7.61 (7.46 - 7.76) 1990 Modelled IHME
2.22 (1.82 - 2.77) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.43 (0.38 - 0.46) 2019 Modelled IHME
0.44 (0.41 - 0.48) 2018 Modelled IHME
0.47 (0.43 - 0.51) 2017 Modelled IHME
0.5 (0.46 - 0.55) 2016 Modelled IHME
0.55 (0.49 - 0.61) 2015 Modelled IHME
0.62 (0.56 - 0.68) 2014 Modelled IHME
0.7 (0.64 - 0.76) 2013 Modelled IHME
0.81 (0.74 - 0.88) 2012 Modelled IHME
0.95 (0.86 - 1.04) 2011 Modelled IHME
1.13 (1.01 - 1.24) 2010 Modelled IHME
1.64 (1.48 - 1.79) 2009 Modelled IHME
2.56 (2.31 - 2.80) 2008 Modelled IHME
3.6 (3.25 - 3.95) 2007 Modelled IHME
4.48 (4.08 - 4.93) 2006 Modelled IHME
4.89 (4.44 - 5.41) 2005 Modelled IHME
4.97 (4.51 - 5.48) 2004 Modelled IHME
5.02 (4.56 - 5.52) 2003 Modelled IHME
5.05 (4.58 - 5.55) 2002 Modelled IHME
5.09 (4.59 - 5.60) 2001 Modelled IHME
5.14 (4.60 - 5.66) 2000 Modelled IHME
5.21 (4.73 - 5.71) 1999 Modelled IHME
5.31 (4.84 - 5.75) 1998 Modelled IHME
5.4 (4.97 - 5.85) 1997 Modelled IHME
5.5 (5.06 - 5.94) 1996 Modelled IHME
5.57 (5.09 - 6.04) 1995 Modelled IHME
5.62 (5.16 - 6.10) 1994 Modelled IHME
5.68 (5.21 - 6.15) 1993 Modelled IHME
5.72 (5.25 - 6.21) 1992 Modelled IHME
5.76 (5.25 - 6.29) 1991 Modelled IHME
5.79 (5.25 - 6.37) 1990 Modelled IHME
0.66 (0.46 - 0.91) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
34 (26 - 43) 2019 Modelled IHME
36 (28 - 44) 2018 Modelled IHME
36 (28 - 45) 2017 Modelled IHME
36 (28 - 45) 2016 Modelled IHME
36 (28 - 45) 2015 Modelled IHME
36 (29 - 45) 2014 Modelled IHME
36 (29 - 45) 2013 Modelled IHME
36 (29 - 45) 2012 Modelled IHME
36 (29 - 45) 2011 Modelled IHME
37 (29 - 45) 2010 Modelled IHME
37 (29 - 45) 2009 Modelled IHME
37 (29 - 46) 2008 Modelled IHME
37 (29 - 46) 2007 Modelled IHME
37 (29 - 46) 2006 Modelled IHME
37 (30 - 46) 2005 Modelled IHME
37 (30 - 46) 2004 Modelled IHME
37 (30 - 46) 2003 Modelled IHME
37 (29 - 46) 2002 Modelled IHME
37 (29 - 46) 2001 Modelled IHME
37 (29 - 46) 2000 Modelled IHME
37 (29 - 45) 1999 Modelled IHME
36 (28 - 45) 1998 Modelled IHME
36 (28 - 45) 1997 Modelled IHME
36 (27 - 45) 1996 Modelled IHME
35 (27 - 45) 1995 Modelled IHME
35 (26 - 45) 1994 Modelled IHME
34 (26 - 45) 1993 Modelled IHME
34 (26 - 44) 1992 Modelled IHME
34 (25 - 44) 1991 Modelled IHME
34 (25 - 44) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
76 2018 Survey/reported WHO/UNICEF
81 2017 Survey/reported WHO/UNICEF
85 2016 Survey/reported WHO/UNICEF
87 2015 Survey/reported WHO/UNICEF
1 2014 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
89 2018 Survey/reported WHO/UNICEF
88 2017 Survey/reported WHO/UNICEF
85 2016 Survey/reported WHO/UNICEF
92 2015 Survey/reported WHO/UNICEF
88 2014 Survey/reported WHO/UNICEF
89 2013 Survey/reported WHO/UNICEF
84 2012 Survey/reported WHO/UNICEF
82 2011 Survey/reported WHO/UNICEF
83 2010 Survey/reported WHO/UNICEF
Showing out of
Show more
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
2014
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
% of substance use disorder facilities offering hepatitis testing
None
% of substance use disorder facilities offering hepatitis treatment
None

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
1.43 (1.15 - 1.79) 2019 Modelled IHME
1.42 (1.15 - 1.79) 2018 Modelled IHME
1.42 (1.14 - 1.77) 2017 Modelled IHME
1.4 (1.13 - 1.73) 2016 Modelled IHME
1.38 (1.11 - 1.71) 2015 Modelled IHME
1.38 (1.11 - 1.71) 2014 Modelled IHME
1.39 (1.12 - 1.73) 2013 Modelled IHME
1.39 (1.12 - 1.73) 2012 Modelled IHME
1.4 (1.13 - 1.74) 2011 Modelled IHME
1.4 (1.14 - 1.75) 2010 Modelled IHME
1.41 (1.15 - 1.76) 2009 Modelled IHME
1.42 (1.16 - 1.78) 2008 Modelled IHME
1.43 (1.16 - 1.79) 2007 Modelled IHME
1.44 (1.17 - 1.80) 2006 Modelled IHME
1.45 (1.17 - 1.82) 2005 Modelled IHME
1.46 (1.17 - 1.83) 2004 Modelled IHME
1.46 (1.18 - 1.84) 2003 Modelled IHME
1.47 (1.18 - 1.85) 2002 Modelled IHME
1.47 (1.18 - 1.86) 2001 Modelled IHME
1.48 (1.18 - 1.87) 2000 Modelled IHME
1.48 (1.19 - 1.87) 1999 Modelled IHME
1.48 (1.18 - 1.87) 1998 Modelled IHME
1.49 (1.19 - 1.87) 1997 Modelled IHME
1.49 (1.19 - 1.87) 1996 Modelled IHME
1.49 (1.19 - 1.87) 1995 Modelled IHME
1.49 (1.19 - 1.87) 1994 Modelled IHME
1.48 (1.19 - 1.86) 1993 Modelled IHME
1.48 (1.19 - 1.86) 1992 Modelled IHME
1.47 (1.18 - 1.84) 1991 Modelled IHME
1.46 (1.16 - 1.84) 1990 Modelled IHME
Showing out of
Show more

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
27 (20 - 35) 2019 Modelled IHME
27 (19 - 34) 2018 Modelled IHME
26 (19 - 34) 2017 Modelled IHME
26 (19 - 34) 2016 Modelled IHME
26 (19 - 34) 2015 Modelled IHME
26 (19 - 34) 2014 Modelled IHME
26 (19 - 34) 2013 Modelled IHME
26 (19 - 34) 2012 Modelled IHME
26 (19 - 34) 2011 Modelled IHME
26 (19 - 34) 2010 Modelled IHME
26 (19 - 34) 2009 Modelled IHME
26 (19 - 34) 2008 Modelled IHME
26 (19 - 34) 2007 Modelled IHME
27 (19 - 34) 2006 Modelled IHME
27 (19 - 34) 2005 Modelled IHME
27 (19 - 34) 2004 Modelled IHME
27 (20 - 34) 2003 Modelled IHME
27 (20 - 35) 2002 Modelled IHME
27 (20 - 35) 2001 Modelled IHME
28 (20 - 35) 2000 Modelled IHME
28 (21 - 36) 1999 Modelled IHME
29 (21 - 37) 1998 Modelled IHME
29 (21 - 37) 1997 Modelled IHME
30 (21 - 38) 1996 Modelled IHME
30 (21 - 39) 1995 Modelled IHME
31 (21 - 40) 1994 Modelled IHME
31 (21 - 41) 1993 Modelled IHME
31 (21 - 41) 1992 Modelled IHME
32 (21 - 42) 1991 Modelled IHME
32 (21 - 42) 1990 Modelled IHME
Showing out of
Show more
Technical notes
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
2014
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
% of substance use disorder facilities offering hepatitis testing
None
% of substance use disorder facilities offering hepatitis treatment
None

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
4.19 (%)
2019
(4.13 - 4.24(%))
IHME
HCV (RNA/cAg+)
1.43 (%)
2019
(1.15 - 1.79(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
82
2019
(55 - 120)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
115
2019
(74 - 167)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.43 (%)
2019, latest modelled
(0.38 - 0.46(%))
IHME

Prevalence PWID

No data available

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
76 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines